Jianying Dong

US Patent:

20090130105, May 21, 2009

Filed:

Aug 28, 2008

Appl. No.:

12/200816

Inventors:

Scott Glaser - San Diego CA, US
Stephen Demarest - San Diego CA, US
Brian Robert Miller - San Diego CA, US
Kandasamy Hariharan - San Diego CA, US
Steffan Ho - San Diego CA, US
Jianying Dong - San Diego CA, US
Alexey Alexandrovich Lugovskoy - Woburn MA, US

Assignee:

Biogen Idec MA Inc. - Cambridge MA

International Classification:

A61K 39/395
C07K 16/00
C07H 21/00
C12N 15/63
C12N 5/10
C12P 21/00
A61P 35/00

US Classification:

4241361, 4241301, 5303892, 5303873, 536 231, 4353201, 435325, 435 696

Abstract:

The instant invention is based, at least in part on the finding that binding molecules which bind to different epitopes within IGF-1R result in improved IGF-1 and/or IGF-2 blocking capabilities when compared to binding molecules that bind to a single IGF-1R epitope. The instant invention provides compositions that bind to multiple epitopes of IGF-1R, for example, combinations of monospecific binding molecules or multispecific binding molecules (e.g., bispecific molecules). Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize IGF-1R signaling are also provided.

US Patent:

20090291088, Nov 26, 2009

Filed:

Apr 10, 2009

Appl. No.:

12/422045

Inventors:

Kandasamy Hariharan - San Diego CA, US
Jianying Dong - San Diego CA, US

Assignee:

Biogen Idec MA Inc. - Cambridge MA

International Classification:

A61K 39/395
A61P 35/00

US Classification:

4241451, 4241581

Abstract:

The invention relates to methods of treatment using combination therapy wherein a variety of therapeutically useful compounds may be combined with antibodies which bind to insulin-like growth factor receptor-1 (IGF-1R). Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention particularly includes methods of treating cancer using combination therapies with IGF-1R antibodies.

US Patent:

20100158926, Jun 24, 2010

Filed:

Aug 2, 2007

Appl. No.:

12/376196

Inventors:

Sue Cartilage - Cheshire, GB
Jianying Dong - San Diego CA, US
Mark Hickinson - Cheshire, GB
Ian Foltz - British Columbia, CA
Singh Japal Kang - British Columbia, CA

Assignee:

ASTRAZENECA AB - Sodertalje

International Classification:

A61K 39/395
C07K 16/30
C07H 21/00
C12N 15/63
C12N 5/00
C12P 21/00
A61P 35/00

US Classification:

4241741, 5303897, 5303873, 53038822, 53038815, 536 231, 4353201, 435325, 435 696, 435375

Abstract:

The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically hind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

US Patent:

20130089544, Apr 11, 2013

Filed:

Dec 11, 2012

Appl. No.:

13/710883

Inventors:

MedImmune Limited - Cambridge, GB
Jianying Dong - San Diego CA, US
Mark Hickinson - Macclesfield, GB
Ian Foltz - British Columbia, CA
Jaspal Singh Kang - British Columbia, CA

Assignee:

MedImmune Limited - Cambridge

International Classification:

C07K 16/40
A61K 45/06
A61K 39/395

US Classification:

4241331, 5303877, 5303873, 4241381, 536 2353, 4353201, 800 13, 800298, 435 696, 435184, 800 6, 435330

Abstract:

The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention

US Patent:

20180250395, Sep 6, 2018

Filed:

Nov 17, 2015

Appl. No.:

15/527551

Inventors:

- Beerse, BE
Jianying Dong - San Diego CA, US
Rosa Cardoso - North Wales PA, US
Hong Zhou - Sand Diego CA, US

Assignee:

Janssen Pharmaceutica NV - Beerse

International Classification:

A61K 39/395
C07K 16/28

Abstract:

The present disclosure relates generally to monoclonal antibodies that specifically bind to CD47, more specifically to CD47 antibodies that do not have significant platelet aggregation activity and do not have significant hemagglutination activity. Methods of generating these antibodies and methods of using these monoclonal antibodies as therapeutics are also provided.